Medeon Biodesign, Inc. (TPEX:6499)
Taiwan
· Delayed Price · Currency is TWD 44.65
+0.95 (2.17%)
Apr 2, 2025, 1:30 PM CST
Medeon Biodesign Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 292.81 | 196.26 | 298.32 | 68.96 | 123.06 | Upgrade
|
| Revenue Growth (YoY) | 49.19% | -34.21% | 332.61% | -43.96% | -72.88% | Upgrade
|
| Cost of Revenue | 209.39 | 181.89 | 111.51 | 40.33 | 76.75 | Upgrade
|
| Gross Profit | 83.41 | 14.38 | 186.81 | 28.63 | 46.3 | Upgrade
|
| Selling, General & Admin | 203.75 | 185.91 | 153.03 | 108.35 | 98.5 | Upgrade
|
| Research & Development | 751.87 | 667.46 | 521.62 | 415.87 | 289.94 | Upgrade
|
| Operating Expenses | 969.03 | 853.94 | 674.65 | 524.22 | 388.05 | Upgrade
|
| Operating Income | -885.61 | -839.57 | -487.84 | -495.59 | -341.75 | Upgrade
|
| Interest Expense | -5.56 | -6.64 | -5.21 | -1.03 | -1.39 | Upgrade
|
| Interest & Investment Income | 20.17 | 19.94 | 10.29 | 6.12 | 9.61 | Upgrade
|
| Earnings From Equity Investments | - | 13.54 | 47.69 | 19.66 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 14.43 | -6.19 | 15.35 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.2 | 0.39 | 0.34 | -43.07 | -8.59 | Upgrade
|
| EBT Excluding Unusual Items | -856.37 | -818.53 | -419.38 | -513.91 | -342.12 | Upgrade
|
| Gain (Loss) on Sale of Investments | -2.28 | -399.15 | -19.73 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -13.01 | - | - | - | Upgrade
|
| Pretax Income | -858.64 | -1,231 | -439.12 | -513.91 | -342.12 | Upgrade
|
| Income Tax Expense | 11.88 | 39.29 | 57.79 | 72.46 | 5.28 | Upgrade
|
| Earnings From Continuing Operations | -870.52 | -1,270 | -496.9 | -586.36 | -347.4 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | 2,618 | 177.81 | Upgrade
|
| Net Income to Company | -870.52 | -1,270 | -496.9 | 2,031 | -169.59 | Upgrade
|
| Minority Interest in Earnings | 65.01 | 65.36 | 63.14 | 46.75 | -23.15 | Upgrade
|
| Net Income | -805.51 | -1,205 | -433.76 | 2,078 | -192.74 | Upgrade
|
| Net Income to Common | -805.51 | -1,205 | -433.76 | 2,078 | -192.74 | Upgrade
|
| Shares Outstanding (Basic) | 92 | 92 | 92 | 92 | 92 | Upgrade
|
| Shares Outstanding (Diluted) | 92 | 92 | 92 | 92 | 92 | Upgrade
|
| Shares Change (YoY) | 0.11% | 0.02% | -0.07% | 0.48% | 0.05% | Upgrade
|
| EPS (Basic) | -8.74 | -13.09 | -4.71 | 22.65 | -2.10 | Upgrade
|
| EPS (Diluted) | -8.74 | -13.09 | -4.71 | 22.65 | -2.10 | Upgrade
|
| Free Cash Flow | -906.97 | -810.36 | -601.91 | -301.69 | -171.44 | Upgrade
|
| Free Cash Flow Per Share | -9.84 | -8.80 | -6.54 | -3.28 | -1.87 | Upgrade
|
| Dividend Per Share | - | - | 0.476 | 0.794 | - | Upgrade
|
| Dividend Growth | - | - | -40.00% | - | - | Upgrade
|
| Gross Margin | 28.49% | 7.32% | 62.62% | 41.52% | 37.63% | Upgrade
|
| Operating Margin | -302.45% | -427.78% | -163.53% | -718.69% | -277.72% | Upgrade
|
| Profit Margin | -275.10% | -613.78% | -145.40% | 3013.75% | -156.62% | Upgrade
|
| Free Cash Flow Margin | -309.75% | -412.90% | -201.77% | -437.51% | -139.31% | Upgrade
|
| EBITDA | -839.21 | -797.3 | -459.64 | -463.09 | -284.45 | Upgrade
|
| EBITDA Margin | -286.61% | - | -154.08% | - | -231.16% | Upgrade
|
| D&A For EBITDA | 46.4 | 42.26 | 28.2 | 32.5 | 57.3 | Upgrade
|
| EBIT | -885.61 | -839.57 | -487.84 | -495.59 | -341.75 | Upgrade
|
| EBIT Margin | - | - | -163.53% | - | -277.72% | Upgrade
|
Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.